Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 12;17(6):771.
doi: 10.3390/pharmaceutics17060771.

Click on Click: Click-Flavone Glycosides Encapsulated in Click-Functionalised Polymersomes for Glioblastoma Therapy

Affiliations

Click on Click: Click-Flavone Glycosides Encapsulated in Click-Functionalised Polymersomes for Glioblastoma Therapy

Nuno M Saraiva et al. Pharmaceutics. .

Abstract

In this study, three new 3,7-dihydroxyflavone (1) derivatives with different sugars were designed and synthesised by click chemistry. Click chemistry requires the previously modification of building blocks with azide and alkyne groups and therefore, the 3,7-dihydroxyflavone (1) was first converted in 3,7-(prop-2-yn-yloxy)flavone (2) and acetobromo-α-D-glucose (3) was converted into 2,3,4,6-tetra-O-acetyl-β-glucopyranosyl azide (4). Subsequently, a click reaction was performed via copper-catalysed cycloaddition (CuAAC) between 2 and 4, as well as between 2 and 2-acetamido-3,4,6-tetra-O-acetyl-2-deoxy-β-D-glucopyranosyl (AG931) and, 2 and commercial 2-azidoethyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl (AG358), resulting in three distinct disubstituted flavone glycosides (5a-5c). Biological assays performed on L929 fibroblast cell lines and human glioblastoma astrocytoma U-251 cell lines indicated cytocompatibility with fibroblasts and reduced metabolic activity of GBM cells in the presence of compound 5b and 5c. To enhance therapeutic effect, improve local drug delivery, and overcome solubility issues of these high molecular weight compounds, the synthesised compounds were encapsulated in polymeric particles (polymersomes, PMs) composed of polylactic acid-polyethylene glycol (PEG-PLA) functionalized, once more by click chemistry, with 0.1 mol% transferrin mimetic (T7-HRPYIAH) peptide. The PMs were prepared by solvent displacement and exhibited stability over 100 days, encapsulation efficiency of 39-93%, and mean size diameters of 120-180 nm. The toxicity assays of the PMs on the U-251 cell line showed a significant decrease in metabolic activity, supporting the potential of this delivery system against GBM. Among the PMs tested, the flavone 5c-based PM demonstrated the highest efficacy.

Keywords: click chemistry; drug delivery; flavones; glioblastoma; polymersome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Scheme 1
Scheme 1
Synthesis of 3,7-(prop-2-yn-yloxy) flavone (2) and 2,3,4,6 tetra-O-Acetyl-β-D-glucopyranosyl azide (4). (i) Propargyl bromide, Tetrabutylammonium hydrogen sulphate (TBAHS), Cs2CO3, acetone, 60 °C, 8 days; (ii) NaN3, acetone:water, room temperature, 4 h.
Scheme 2
Scheme 2
Synthesis of flavonoids 5a5c. (i) 5a: 4, THF: water, room temperature, 24 h; 5b: AG931, THF: water, room temperature, 2 h; 5c: AG358, THF: water, room temperature, 2 h. Ac = Acetyl (COCH3).
Figure 1
Figure 1
Main connectivities found in HMBC for the identification of the triazole ring positions.
Figure 2
Figure 2
Cell viability (%) effect on (a) the fibroblast L929 cell line and (b) the human glioblastoma astrocytoma U-251 cell line of free synthesised compounds. Each value represents a total of n = 3 replicates of n = 3 independent assays (a total of 9 replicates). DMEM was used as a positive control and 1% Triton X-100 as a negative control. * (One asterisk): p-value <0.05; ** (Two asterisks): p-value < 0.01; *** (Three asterisks): p-value < 0.001; **** (Four asterisks): p-value < 0.0001.
Figure 3
Figure 3
Entrapment efficiency (EE%) of the compounds synthesised (a) and TEM images of the formulations 0 mol% T7-PEGPLA (control) (b), 0.1 mol% T7-PEGPLA (control) (c), 0.1 mol% T7-PEGPLA-5a (d), 0.1 mol% T7-PEGPLA-5b (e), and 0.1 mol% T7-PEGPLA-5c (f).
Figure 3
Figure 3
Entrapment efficiency (EE%) of the compounds synthesised (a) and TEM images of the formulations 0 mol% T7-PEGPLA (control) (b), 0.1 mol% T7-PEGPLA (control) (c), 0.1 mol% T7-PEGPLA-5a (d), 0.1 mol% T7-PEGPLA-5b (e), and 0.1 mol% T7-PEGPLA-5c (f).
Figure 4
Figure 4
Effective mean diameter (a) and zeta potential (b) of functionalised PMs formulations stored at 4 °C for 100 consecutive days (each value represents a total of n = 3 replicates). The Size (nm) y-axis is presented in a logarithmical (log10) scale.
Figure 5
Figure 5
Cell viability (%) effect on the human glioblastoma astrocytoma U-251 cell line of loaded PMs with synthesised flavones. Each value represents a total of n = 3 replicates of n = 3 independent assays (a total of 9 replicates). DMEM was used as the positive control and 1% Triton X-100 as a negative control. **** (Four asterisks): p-value < 0.0001.

Similar articles

References

    1. Pourgholi F., Hajivalili M., Farhad J.-N., Kafil H.S., Yousefi M. Nanoparticles: Novel Vehicles in Treatment of Glioblastoma. Biomed. Pharmacother. 2016;77:98–107. doi: 10.1016/j.biopha.2015.12.014. - DOI - PubMed
    1. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant Astrocytic Glioma: Genetics, Biology, and Paths to Treatment. Genes Dev. 2007;21:2683–2710. doi: 10.1101/gad.1596707. - DOI - PubMed
    1. Esiri M.M., Oppenheimer D.R. Oppenheimer’s Diagnostic Neuropathology: A Practical Manual. 3rd ed. Volume 33 Blackwell Scientific Publications; Oxford, UK: 2007.
    1. Vanza J., Jani P., Pandya N., Tandel H. Formulation and Statistical Optimization of Intravenous Temozolomide-Loaded PEGylated Liposomes to Treat Glioblastoma Multiforme by Three-Level Factorial Design. Drug Dev. Ind. Pharm. 2018;44:923–933. doi: 10.1080/03639045.2017.1421661. - DOI - PubMed
    1. Morais L.C., Queiroz V.C.J., Cavalcante J.E.S., Matozinho H.H.S., Silva F.H.R., Costa M.G.P., Pereira I F.Y., Tavares L.C.P., Guimarães G.M. Treatment and Prognosis of Glioblastoma Multiforme: A Literature Review. J. Neurol. Sci. 2015;357:e183. doi: 10.1016/j.jns.2015.08.630. - DOI

LinkOut - more resources